Clinical evaluation of a sub-lingual vaccine for prevention of exacerbations in COPD
Background: Lower airway bacterial infection is one of the major cause for exacerbation inCOPD. Multicomponent vaccines derived from the various causative pathogens are shownto prevent the exacerbations. Aims and Objectives: The present study was carried out toevaluate the effi cacy of sublingual...
| 第一著者: | |
|---|---|
| フォーマット: | 論文 |
| 言語: | English |
| 出版事項: |
Manipal College of Medical Sciences, Pokhara
2016-02-01
|
| シリーズ: | Asian Journal of Medical Sciences |
| 主題: | |
| オンライン･アクセス: | https://www.nepjol.info/index.php/AJMS/article/view/11634 |
| _version_ | 1828761196102156288 |
|---|---|
| author | P.D. Nadig |
| author_facet | P.D. Nadig |
| author_sort | P.D. Nadig |
| collection | DOAJ |
| description | Background: Lower airway bacterial infection is one of the major cause for exacerbation inCOPD. Multicomponent vaccines derived from the various causative pathogens are shownto prevent the exacerbations.
Aims and Objectives: The present study was carried out toevaluate the effi cacy of sublingual vaccine (Ismigen) in preventing the exacerbations inCOPD and to observe its tolerability.
Materials and Methods: Twenty four COPD patientsmeeting the eligibility criteria were enrolled in the study. Ismigen was administered once aday sublingually for ten days a month for three consecutive months. They were observed over one year for exacerbations, hospitalisations, respiratory symptoms, lung function tests and adverse reactions. The mean scores of the parameters in the previous year were compared with that of the year following treatment. Students t test and Chi- square test were used for analysis.
Results: The mean number of exacerbations reduced from 6.79±3.51 to 2.67±1.90 (p<0.001) and the mean number of hospitalisations from 2.29±1.85 to 0.67±0.87 (p<0.001). There was no significant change in the respiratory symptom score and lung function test. Mild non-serious adverse event was reported by one patient.
Conclusion: The results indicated that Ismigen could be an effective and well-tolerated add on therapy in COPD to reduce the frequency and severity of exacerbations. |
| first_indexed | 2024-12-11T01:25:57Z |
| format | Article |
| id | doaj.art-f14ef068b10b45d4b879fae922fd2912 |
| institution | Directory Open Access Journal |
| issn | 2467-9100 2091-0576 |
| language | English |
| last_indexed | 2024-12-11T01:25:57Z |
| publishDate | 2016-02-01 |
| publisher | Manipal College of Medical Sciences, Pokhara |
| record_format | Article |
| series | Asian Journal of Medical Sciences |
| spelling | doaj.art-f14ef068b10b45d4b879fae922fd29122022-12-22T01:25:31ZengManipal College of Medical Sciences, PokharaAsian Journal of Medical Sciences2467-91002091-05762016-02-01625154https://doi.org/10.3126/ajms.v6i4.11634Clinical evaluation of a sub-lingual vaccine for prevention of exacerbations in COPDP.D. Nadig 0Professor, Department of Pharmacology, Vydehi Institute of Medical Sciences and Research Centre, Bangalore, KarnatakaBackground: Lower airway bacterial infection is one of the major cause for exacerbation inCOPD. Multicomponent vaccines derived from the various causative pathogens are shownto prevent the exacerbations. Aims and Objectives: The present study was carried out toevaluate the effi cacy of sublingual vaccine (Ismigen) in preventing the exacerbations inCOPD and to observe its tolerability. Materials and Methods: Twenty four COPD patientsmeeting the eligibility criteria were enrolled in the study. Ismigen was administered once aday sublingually for ten days a month for three consecutive months. They were observed over one year for exacerbations, hospitalisations, respiratory symptoms, lung function tests and adverse reactions. The mean scores of the parameters in the previous year were compared with that of the year following treatment. Students t test and Chi- square test were used for analysis. Results: The mean number of exacerbations reduced from 6.79±3.51 to 2.67±1.90 (p<0.001) and the mean number of hospitalisations from 2.29±1.85 to 0.67±0.87 (p<0.001). There was no significant change in the respiratory symptom score and lung function test. Mild non-serious adverse event was reported by one patient. Conclusion: The results indicated that Ismigen could be an effective and well-tolerated add on therapy in COPD to reduce the frequency and severity of exacerbations.https://www.nepjol.info/index.php/AJMS/article/view/11634exacerbationinfectionsublingualvaccine |
| spellingShingle | P.D. Nadig Clinical evaluation of a sub-lingual vaccine for prevention of exacerbations in COPD Asian Journal of Medical Sciences exacerbation infection sublingual vaccine |
| title | Clinical evaluation of a sub-lingual vaccine for prevention of exacerbations in COPD |
| title_full | Clinical evaluation of a sub-lingual vaccine for prevention of exacerbations in COPD |
| title_fullStr | Clinical evaluation of a sub-lingual vaccine for prevention of exacerbations in COPD |
| title_full_unstemmed | Clinical evaluation of a sub-lingual vaccine for prevention of exacerbations in COPD |
| title_short | Clinical evaluation of a sub-lingual vaccine for prevention of exacerbations in COPD |
| title_sort | clinical evaluation of a sub lingual vaccine for prevention of exacerbations in copd |
| topic | exacerbation infection sublingual vaccine |
| url | https://www.nepjol.info/index.php/AJMS/article/view/11634 |
| work_keys_str_mv | AT pdnadig clinicalevaluationofasublingualvaccineforpreventionofexacerbationsincopd |